Forte Biosciences (FBRX) Cash & Equivalents Growth (3y) (2019 - 2026)
Forte Biosciences (FBRX) Cash & Equivalents Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 13.29% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.63% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -16.07% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.88% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 47.78% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Forte Biosciences | 1.37 Bn | 1.31 Bn | - | 17.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.47% |
| Dec 31, 2025 | 23.25% |
| Sep 30, 2025 | 28.47% |
| Jun 30, 2025 | 40.20% |
| Mar 31, 2025 | 4.63% |
| Dec 31, 2024 | -19.12% |
| Sep 30, 2024 | -28.92% |
| Jun 30, 2024 | -21.58% |
| Mar 31, 2024 | -17.77% |
| Dec 31, 2023 | -14.19% |
| Sep 30, 2023 | 31.74% |
| Jun 30, 2023 | -9.69% |
| Mar 31, 2023 | 36.13% |
| Dec 31, 2022 | 80.93% |
| Sep 30, 2022 | 19.86% |
| Jun 30, 2022 | 26.77% |
| Mar 31, 2022 | 8.90% |
| Dec 31, 2021 | 1.00% |
| Sep 30, 2021 | 24.82% |
| Jun 30, 2021 | 27.32% |